Park Kee Hyung, Jang Jae-Won, Suh Jeewon, Yi SangHak, Bae Jae-Sung, Lim Jae-Sung, Lee Hyon, Chin Juhee, Park Young Ho, Hong Yun Jeong, Kim Geon Ha
Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Department of Neurology, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea.
Dement Neurocogn Disord. 2022 Apr;21(2):45-58. doi: 10.12779/dnd.2022.21.2.45. Epub 2022 Mar 14.
Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer's dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD's diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.
最近，一种针对β淀粉样蛋白的免疫疗法药物阿杜卡奴单抗已获美国食品药品监督管理局批准用于治疗阿尔茨海默病性痴呆（AD）。尽管仍有许多问题有待解答，但这一批准为AD药物的研发带来了充满希望的曙光，有望得到新型生物标志物（如基于血液的生物标志物）以及能够确认AD早期病理变化的综合神经心理学测试的支持。阐明已知与血管病因和神经炎症等其他因素相关的AD的复杂性非常重要。通过韩国痴呆症协会（KDA）的第二届国际会议，来自世界各地的研究人员与KDA成员就最新话题进行了意见交流。KDA学术委员会对讲座进行总结，以呈现会议的深度以及讨论情况。这将是拓宽AD诊断、治疗、发病机制研究最新知识的一个重要里程碑，有助于确立未来的研究方向。
